📊 OTLK Key Takeaways
Is Outlook Therapeutics, Inc. (OTLK) a Good Investment?
Outlook Therapeutics demonstrates impressive revenue growth (+599% YoY) from recent product commercialization, but faces existential financial distress with negative stockholders equity, severe liquidity crisis (0.54x current ratio), and monthly cash burn of ~$1.9M leaving only 4 months of runway at current levels. The company must achieve an immediate capital raise or dramatic path to profitability to survive.
Outlook Therapeutics is pre-revenue with deep operating and net losses, negative free cash flow, and negative gross profit. Liquidity is severely strained (current ratio 0.35) alongside negative equity and substantial long-term debt with negative interest coverage, indicating elevated solvency and financing risk. Without a clear path to revenue or a sharp reduction in burn, fundamentals remain highly unfavorable.
Outlook Therapeutics, Inc. Key Strengths (OTLK)
- Strong revenue growth of +599.3% YoY indicates successful product commercialization
- EPS loss narrowing (+55.9% improvement) shows loss reduction trajectory
- Minimal capital expenditure ($437K) suggests capital-efficient business model
- Low capital expenditure needs support an asset-light model
- EPS loss narrowed YoY, suggesting some expense discipline
- Cash on hand provides limited near-term flexibility
OTLK Stock Risks: Outlook Therapeutics, Inc. Investment Risks
- Negative stockholders equity of -$29.0M represents technical insolvency and balance sheet deterioration
- Critical liquidity crisis with current ratio of 0.54x; current liabilities exceed current assets by $18M
- Severe cash burn: -$23.2M free cash flow with only $7.7M cash on hand creates 4-month survival runway
- Unprofitable at every level: -$1.3M gross profit, -$27.5M operating loss, negative operating cash flow
- No insider buying activity signals lack of management confidence in near-term recovery
- Severe liquidity stress with sub-1.0 current and quick ratios
- Negative equity and high leverage with negative interest coverage
- Sustained cash burn and zero revenue imply ongoing dilution/financing risk
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway projections
- Revenue growth sustainability and gross margin path to positive
- Operating expense reduction initiatives and timeline to cash flow breakeven
- Operating cash flow (quarterly)
- Cash and equivalents
Outlook Therapeutics, Inc. (OTLK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OTLK Profit Margin, ROE & Profitability Analysis
OTLK vs Healthcare Sector: How Outlook Therapeutics, Inc. Compares
How Outlook Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Outlook Therapeutics, Inc. Stock Overvalued? OTLK Valuation Analysis 2026
Based on fundamental analysis, Outlook Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Outlook Therapeutics, Inc. Balance Sheet: OTLK Debt, Cash & Liquidity
OTLK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Outlook Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.06 indicates the company is currently unprofitable.
OTLK Revenue Growth, EPS Growth & YoY Performance
OTLK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.5M | -$11.2M | $-0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Outlook Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
OTLK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Outlook Therapeutics, Inc. (CIK: 0001649989)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OTLK
What is the AI rating for OTLK?
Outlook Therapeutics, Inc. (OTLK) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OTLK's key strengths?
Claude: Strong revenue growth of +599.3% YoY indicates successful product commercialization. EPS loss narrowing (+55.9% improvement) shows loss reduction trajectory. ChatGPT: Low capital expenditure needs support an asset-light model. EPS loss narrowed YoY, suggesting some expense discipline.
What are the risks of investing in OTLK?
Claude: Negative stockholders equity of -$29.0M represents technical insolvency and balance sheet deterioration. Critical liquidity crisis with current ratio of 0.54x; current liabilities exceed current assets by $18M. ChatGPT: Severe liquidity stress with sub-1.0 current and quick ratios. Negative equity and high leverage with negative interest coverage.
What is OTLK's revenue and growth?
Outlook Therapeutics, Inc. reported revenue of $3.0.
Does OTLK pay dividends?
Outlook Therapeutics, Inc. does not currently pay dividends.
Where can I find OTLK SEC filings?
Official SEC filings for Outlook Therapeutics, Inc. (CIK: 0001649989) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OTLK's EPS?
Outlook Therapeutics, Inc. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OTLK's fundamental grade?
Based on our AI fundamental analysis in May 2026, Outlook Therapeutics, Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OTLK stock overvalued or undervalued?
Valuation metrics for OTLK: ROE of N/A (sector avg: 15%), net margin of -917,040,533.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OTLK's AI grade for 2026?
Our dual AI analysis gives Outlook Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OTLK's free cash flow?
Outlook Therapeutics, Inc.'s operating cash flow is $-22.8M, with capital expenditures of $437.3K. FCF margin is -773,482,433.3%.
How does OTLK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -917,040,533.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.54 (avg: 2).